<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="http://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:voc="urn:hl7-org:v3/voc" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 http://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="45ae1464-52ad-4b2b-9786-f6351a9add9d"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use ILEVRO<sup>*</sup> safely and effectively. See full prescribing information for ILEVRO.<br/>
         <br/>ILEVRO<sup>*</sup> (nepafenac ophthalmic suspension) 0.3%, topical ophthalmic<br/>Initial U.S. Approval: 2005</content>
   </title>
   <effectiveTime value="20190909"/>
   <setId root="6c212466-ff8d-ecfc-ede2-ef8bdcaaf114"/>
   <versionNumber value="15"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="008018525" root="1.3.6.1.4.1.519.1"/>
            <name>Alcon Laboratories, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="79e9b760-d22d-4446-8f14-1ccf0d3a46e7"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20181213"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0065-1750" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ILEVRO </name>
                        <formCode code="C42994" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUSPENSION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>nepafenac</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="3"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0J9L7J6V8C" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Nepafenac</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0J9L7J6V8C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>Nepafenac</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R57ZHV85D4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Boric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Propylene Glycol</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HHT01ZNK31" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Carbomer Homopolymer Type B (allyl Pentaerythritol Crosslinked)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="451W47IQ8X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="E89I1637KE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Guar Gum</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="K679OBS311" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Carboxymethylcellulose Sodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Edetate Disodium</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Benzalkonium Chloride</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Sodium Hydroxide</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Hydrochloric Acid</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>Water</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="1.7"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0065-1750-07" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20121220"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value="3"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0065-1750-14" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20121220"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="mL" value=".8"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43171" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, DROPPER"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0065-1750-08" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20121220"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20121220"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <approval>
                           <id extension="NDA203491" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <component>
                  <observationMedia ID="MM36792">
                     <text>Chemical Diagram</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="chemical.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM36793">
                     <text>Carton 1.7 mL</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7C1F1C24-0EE0-988C-5EE7-01AA47325249">
               <id root="e5190fd1-6c39-4c32-9cf5-bb56e1a55c43"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ILEVRO<sup>*</sup> 0.3% is indicated for the treatment of pain and inflammation associated with cataract surgery.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ILEVRO<sup>*</sup> 0.3% is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of pain and inflammation associated with cataract surgery <linkHtml href="#ID_7C1F1C24-0EE0-988C-5EE7-01AA47325249">(1)</linkHtml>.</paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_BCE1A361-8972-9EB4-24D5-4030DD22DEAC">
               <id root="ca185580-ecb9-44e7-9bb4-0f287a10a892"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>One drop of ILEVRO<sup>*</sup> 0.3% should be applied to the affected eye one-time-daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery. <linkHtml href="#ID_BCE1A361-8972-9EB4-24D5-4030DD22DEAC">(2)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_75174569-a4a6-c96a-11e1-783189653947">
                     <id root="c9b45847-db92-4a63-9968-e0b80f012377"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1  Recommended Dosing</title>
                     <text>
                        <paragraph>One drop of ILEVRO<sup>*</sup> 0.3% should be applied to the affected eye one time daily beginning 1 day prior to cataract surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. An additional drop should be administered 30 to 120 minutes prior to surgery.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_2a8e350c-066c-0fb1-3711-55cf3171465b">
                     <id root="53b3024e-d597-43fe-b7a0-ba7c4e3907e9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Use with Other Topical Ophthalmic Medications</title>
                     <text>
                        <paragraph>ILEVRO<sup>*</sup> 0.3% may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.<br/>
                           <br/>If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_B092607F-72D4-0F25-3005-FD435515615D">
               <id root="2ffd6d0b-b1df-4106-83d8-50bc0bb9e9a9"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Sterile ophthalmic suspension 0.3%: 1.7 mL in a 4 mL bottle and 3 mL in a 4 mL bottle.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Sterile ophthalmic suspension 0.3%: 1.7 mL in a 4 mL bottle and 3 mL in a 4 mL bottle. <linkHtml href="#ID_B092607F-72D4-0F25-3005-FD435515615D">(3)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_8E19135B-B5F2-FB66-E48B-EEB24DDEAA11">
               <id root="f3de1eba-c26e-48ce-906b-8fb67edd710e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>ILEVRO<sup>*</sup> 0.3% is contraindicated in patients with previously demonstrated hypersensitivity to any of the ingredients in the formula or to other nonsteroidal anti-inflammatory drugs (NSAIDs).</paragraph>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hypersensitivity to any of the ingredients in the formula or to other non-steroidal anti-inflammatory drugs (NSAIDS). <linkHtml href="#ID_8E19135B-B5F2-FB66-E48B-EEB24DDEAA11">(4)</linkHtml>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="ID_55B36CCB-1269-A514-5DC7-00B0897FFD33">
               <id root="c1a9c880-6131-46bd-a1f0-1431281e79e5"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list>
                           <item>Increased bleeding time due to interference with thrombocyte aggregation (<linkHtml href="#ID_6d419015-164f-a020-b19e-119de48beb58">5.1</linkHtml>)</item>
                           <item>Delayed healing (<linkHtml href="#ID_53a4794b-d9c5-cc21-1169-5ddd7aafdbd0">5.2</linkHtml>)</item>
                           <item>Corneal effects including keratitis (<linkHtml href="#ID_aebcf137-5879-3298-bb32-b5f24e562076">5.3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_6d419015-164f-a020-b19e-119de48beb58">
                     <id root="d0bebd0a-8603-4bcb-8194-ee0894c99e41"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Increased Bleeding Time</title>
                     <text>
                        <paragraph>With some NSAIDS including ILEVRO<sup>*</sup> 0.3%, there exists the potential for increased bleeding time due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphema) in conjunction with ocular surgery.</paragraph>
                        <paragraph>It is recommended that ILEVRO<sup>*</sup> 0.3% be used with caution in patients with known bleeding tendencies or who are receiving other medications which may prolong bleeding time.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_53a4794b-d9c5-cc21-1169-5ddd7aafdbd0">
                     <id root="91dd9ed8-5a36-47ac-81ab-77c6bc417219"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Delayed Healing</title>
                     <text>
                        <paragraph>Topical NSAIDs including ILEVRO<sup>*</sup> 0.3%, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_aebcf137-5879-3298-bb32-b5f24e562076">
                     <id root="da9210c7-5c44-4ace-b9c6-eee272fc0663"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Corneal Effects</title>
                     <text>
                        <paragraph>Use of topical NSAIDs may result in keratitis. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, corneal thinning, corneal erosion, corneal ulceration, or corneal perforation. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs including ILEVRO<sup>*</sup> 0.3% and should be closely monitored for corneal health.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events, which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</paragraph>
                        <paragraph>Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post-surgery may increase patient risk and severity of corneal adverse events.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f3a7ad9b-3271-bb39-77d0-6cf1a7edc3f6">
                     <id root="c0273b1f-e72c-44ea-b338-07c134f2b1aa"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Contact Lens Wear</title>
                     <text>
                        <paragraph>ILEVRO<sup>*</sup> 0.3% should not be administered while using contact lenses.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_0B82536A-81B8-14A7-8751-2E57AF8BA925">
               <id root="5a971dc7-5029-4562-a9c4-034aa6e31bc9"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions (5% to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure, and sticky sensation. (<linkHtml href="#ID_20b9cf7e-54d4-f58e-45d2-f190896b9115">6.1</linkHtml>)<content styleCode="bold"/>
                           <br/>
                           <content styleCode="bold">
                              <br/>To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc. at 1-800-757-9195 or FDA at 1-800-FDA-1088 or <linkHtml href="www.fda.gov/medwatch">www.fda.gov/medwatch</linkHtml>.</content>
                        </paragraph>
                        <br/>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="ID_20b9cf7e-54d4-f58e-45d2-f190896b9115">
                     <id root="380f3e2d-a06a-42e5-99a7-b03a7ba30046"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Serious and Otherwise Important Adverse Reactions</title>
                     <text>
                        <paragraph>The following adverse reactions are discussed in greater detail in other sections of labeling.</paragraph>
                        <list>
                           <item>Increased Bleeding Time <content styleCode="italics">[see Warnings and Precautions (5.1)]</content>
                           </item>
                           <item>Delayed Healing <content styleCode="italics">[see Warnings and Precautions (5.2)]</content>
                           </item>
                           <item>Corneal Effects <content styleCode="italics">[see Warnings and Precautions (5.3)]</content>
                           </item>
                        </list>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0cc9b844-f4ff-1661-2be5-92602a3bda2d">
                     <id root="e71dfb5b-b73e-4d94-972b-a0bdafeb055d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Ocular Adverse Reactions</title>
                     <text>
                        <paragraph>The most frequently reported ocular adverse reactions following cataract surgery were capsular opacity, decreased visual acuity, foreign body sensation, increased intraocular pressure (IOP), and sticky sensation. These reactions occurred in approximately 5% to 10% of patients.</paragraph>
                        <paragraph>Other ocular adverse reactions occurring at an incidence of approximately 1% to 5% included conjunctival edema, corneal edema, dry eye, lid margin crusting, ocular discomfort, ocular hyperemia, ocular pain, ocular pruritus, photophobia, tearing, and vitreous detachment.</paragraph>
                        <paragraph>Some of these reactions may be the consequence of the cataract surgical procedure.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_46264796-7b54-9deb-d09a-4d665d10424b">
                     <id root="9462a0e4-0777-450f-818f-f8a5aa273356"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.3 Non-Ocular Adverse Reactions</title>
                     <text>
                        <paragraph>Non-ocular adverse reactions reported at an incidence of 1% to 4% included headache, hypertension, nausea/vomiting, and sinusitis.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_6D27F915-6FB9-5C10-ECDB-7B4AD02BD4F7">
               <id root="e2be084d-13c2-4ce0-b53a-28f37862e0fe"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20190131"/>
               <component>
                  <section ID="ID_6ed5e22c-77d6-b485-9b55-8321f12f0985">
                     <id root="5b694241-a522-419f-9422-47d718b29b39"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Teratogenic Effects. <br/>Pregnancy Category C: </content>Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of teratogenicity due to nepafenac, despite the induction of maternal toxicity. At this dose, the animal plasma exposure to nepafenac and amfenac was approximately 70 and 630 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 20 and 180 times human plasma exposure for rabbits, respectively. In rats, maternally toxic doses greater than or equal to 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced fetal weights and growth, and reduced fetal survival.<br/>
                           <br/>Nepafenac has been shown to cross the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, ILEVRO<sup>*</sup>  0.3% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.<br/>
                           <br/>
                           <content styleCode="bold">Non-teratogenic Effects<br/>
                           </content>Because of the known effects of prostaglandin biosynthesis inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of ILEVRO<sup>*</sup> 0.3% during late pregnancy should be avoided.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6f826352-0caa-f915-a64e-269dd253ed73">
                     <id root="185431a5-4330-4947-9dd1-91a70264fc0e"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>8.3 Nursing Mothers</title>
                     <text>
                        <paragraph>Nepafenac is excreted in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when ILEVRO<sup>*</sup> 0.3% is administered to a nursing woman.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_531dddc2-9dcd-cf42-0d4a-72f2ac59304f">
                     <id root="d749b12a-dc1a-423e-b99a-47f7ddfdacbb"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ILEVRO<sup>*</sup> 0.3% in pediatric patients below the age of 10 years have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_22046615-d2b1-3a9c-0a44-6cda13d4c1e0">
                     <id root="71e6e1fb-fb5a-4eed-be14-2a127d2bb31d"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety and effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_A1049A6C-EBF8-3E34-924B-241493C66C90">
               <id root="0f15cab1-2396-48fe-ba6e-ce074356597c"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ILEVRO<sup>*</sup> 0.3% is a sterile, topical, NSAID prodrug for ophthalmic use. Each mL of ILEVRO<sup>*</sup> 0.3% contains 3 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3-benzoylbenzeneacetamide with an empirical formula of C15H14N2O2. The structural formula of nepafenac is:<br/>
                     <br/>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM36792"/>
                  <paragraph>Nepafenac is a yellow crystalline powder. The molecular weight of nepafenac is 254.28 g/mol. ILEVRO<sup>*</sup> 0.3% is supplied as a sterile, aqueous suspension with a pH approximately of 6.8.<br/>
                     <br/>The osmolality of ILEVRO<sup>*</sup> 0.3% is approximately 300 mOsm/kg.<br/>
                     <br/>Each mL of ILEVRO<sup>*</sup> 0.3% contains: <content styleCode="bold">Active:</content> nepafenac 0.3%. <content styleCode="bold">Inactives:</content> boric acid, propylene glycol, carbomer 974P, sodium chloride, guar gum, carboxymethylcellulose sodium, edetate disodium, benzalkonium chloride 0.005% (preservative), sodium hydroxide and/or hydrochloric acid to adjust pH and purified water, USP.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
            </section>
         </component>
         <component>
            <section ID="ID_AA82784F-DBC1-0746-84C3-8FA69F1CA78C">
               <id root="6c2c3c72-04ec-4bdc-b229-2958d552d98f"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20190131"/>
               <component>
                  <section ID="ID_31f9cc53-8450-9b48-3a73-9f028ec20c28">
                     <id root="50e0ab2c-b0fa-47d6-b552-1c180f43e670"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a NSAID. Nepafenac and amfenac are thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_6320999a-47ea-2ce6-3a73-b059408af108">
                     <id root="82341d3e-c2e7-4c10-baa4-05f011e4b49b"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following bilateral topical ocular once-daily dosing of ILEVRO<sup>*</sup> 0.3%, the concentrations of nepafenac and amfenac peaked at a median time of 0.5 hour and 0.75 hour, respectively on both Day 1 and Day 4. The mean steady-state C<sub>max</sub> for nepafenac and for amfenac were 0.847 ± 0.269 ng/mL and 1.13 ± 0.491 ng/mL, respectively.<br/>
                           <br/>Nepafenac at concentrations up to 3000 ng/mL and amfenac at concentrations up to 1000 ng/mL did not inhibit the <content styleCode="italics">in vitro </content>metabolism of six specific marker substrates of cytochrome P450 (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). Therefore, drug-drug interactions involving CYP mediated metabolism of concomitantly administered drugs are unlikely.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_D60A4F76-AA00-4425-DF51-A3B3F8C2ACAC">
               <id root="28ebeb93-3fb0-4ce2-b381-fc9cf9d8e35f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <text>
                  <paragraph/>
               </text>
               <effectiveTime value="20190131"/>
               <component>
                  <section ID="ID_39d2beb2-511f-e8ba-f368-aa3f5b3df3b5">
                     <id root="795b79f3-a889-4fc0-a03a-7e6637dded36"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Nepafenac has not been evaluated in long-term carcinogenicity studies. Increased chromosomal aberrations were observed in Chinese hamster ovary cells exposed <content styleCode="italics">in vitro </content>to nepafenac suspension. Nepafenac was not mutagenic in the Ames assay or in the mouse lymphoma forward mutation assay. Oral doses up to 5000 mg/kg did not result in an increase in the formation of micronucleated polychromatic erythrocytes <content styleCode="italics">in vivo </content>in the mouse micronucleus assay in the bone marrow of mice.<br/>
                           <br/>Nepafenac did not impair fertility when administered orally to male and female rats at 3 mg/kg.</paragraph>
                     </text>
                     <effectiveTime value="20190131"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_BA78AD63-6965-E975-04B1-18F3BD52F626">
               <id root="adc6aa2b-8070-4d29-bf35-729d470c0b54"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>In two double masked, randomized clinical trials in which patients were dosed daily beginning one day prior to cataract surgery, continued on the day of surgery and for the first two weeks of the postoperative period, ILEVRO<sup>*</sup> 0.3% demonstrated superior clinical efficacy compared to its vehicle in treating postoperative pain and inflammation.<br/>
                     <br/>Treatment effect over vehicle for resolution of ocular pain occurred as early as Day 1 postsurgery. Treatment effect over vehicle for resolution of inflammation was significantly better than vehicle in both studies at Day 7 and Day 14 post-surgery.</paragraph>
                  <table border="1" cellpadding="1" rules="all" styleCode="BotruleLruleRruleToprule" width="100%">
                     <caption>Table 1: Inflammation and Ocular Pain Resolution Results of Nepafenac Ophthalmic Suspension, 0.3% versus Vehicle at Day 14 Postsurgery (All-Randomized Population)</caption>
                     <colgroup>
                        <col align="center"/>
                        <col align="center"/>
                        <col align="center"/>
                        <col align="center"/>
                     </colgroup>
                     <thead>
                        <tr styleCode="FirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstLastLastLastLastLastLastLastLastLastLastLastLastLastLastLast">
                           <th align="center" styleCode="Botrule Lrule Rrule Toprule">Study</th>
                           <th align="center" styleCode="Rrule Toprule Botrule">Treatment</th>
                           <th align="center" styleCode="Botrule Lrule Rrule Toprule">Inflammation Resolution <br/>at Postop Day 14</th>
                           <th align="center" styleCode="Lrule Rrule Toprule Botrule">Ocular Pain Resolution <br/>at Postop Day 14</th>
                        </tr>
                     </thead>
                     <tbody>
                        <tr styleCode="FirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirstFirst">
                           <td align="center" rowspan="4" styleCode="Lrule Rrule">Study 1</td>
                           <td align="center" styleCode="Botrule Rrule Toprule">Nepafenac ophthalmic suspension, 0.3% (n/N)<sup>(1)</sup>
                           </td>
                           <td align="center" styleCode="Lrule Rrule Toprule Botrule">552/851 (65%)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">734/851 (86%)</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Toprule Botrule">NEVANAC (n/N)<sup>(1)</sup>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">568/845 (67%)</td>
                           <td align="center" styleCode="Lrule Rrule Toprule Botrule">737/845 (87%)</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Rrule Toprule">Vehicle (n/N)<sup>(1)</sup>
                           </td>
                           <td align="center" styleCode="Lrule Rrule Toprule Botrule">67/211 (32%)</td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">98/211 (46%)</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Rrule Toprule Botrule">Difference (95% CI)<sup>(2)</sup>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">33% (26%, 40%)</td>
                           <td align="center" styleCode="Lrule Rrule Toprule Botrule">40% (32%, 47%)</td>
                        </tr>
                        <tr>
                           <td align="center" rowspan="3" styleCode="Botrule Lrule Rrule Toprule">Study 2</td>
                           <td align="center" styleCode="Rrule Botrule">Nepafenac ophthalmic suspension, 0.3% (n/N)<sup>(1)</sup>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">331/540 (61%)</td>
                           <td align="center" styleCode="Lrule Rrule Toprule Botrule">456/540 (84%)</td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Rrule">Vehicle (n/N)<sup>(1)</sup>
                           </td>
                           <td align="center" styleCode="Botrule Lrule Rrule Toprule">63/268 (24%)</td>
                           <td align="center" styleCode="Lrule Rrule Toprule Botrule">101/268 (38%)</td>
                        </tr>
                        <tr styleCode="LastLastLastLastLastLastLastLastLastLastLastLastLastLastLast">
                           <td align="center" styleCode="Rrule">Difference (95% CI)<sup>(2)</sup>
                           </td>
                           <td align="center" styleCode="Lrule Rrule Toprule">38% (31%, 45%)</td>
                           <td align="center" styleCode="Lrule Rrule Toprule">47% (40%, 54%)</td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>
						Abbreviation: CI, confidence interval.<br/>
                     <sup>(1)</sup>n/N is the ratio of those with complete resolution of anterior chamber cell and flare by the postoperative Day 14 visit over all randomized subjects. <br/>
                     <sup>(2)</sup>Difference is Nepafenac ophthalmic suspension, 0.3% (n/N) – vehicle. The 95% CI is derived using asymptotic approximation.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
            </section>
         </component>
         <component>
            <section ID="ID_7C0820BA-9CCC-A569-F9A1-1AC5BADACDDD">
               <id root="42a82079-2a17-433e-aeab-6bccda3e5360"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>ILEVRO<sup>*</sup> 0.3% is supplied in a white, oval, low density polyethylene DROP-TAINER<sup>®</sup> dispenser with a natural low density polyethylene dispensing plug and gray polypropylene cap. The 1.7 mL fill is presented in an overwrap, which provides tamper evidence to the package. Tamper evidence for the 3 mL fill is provided with a shrink band around the closure and neck area of the package.</paragraph>
                  <paragraph>1.7 mL in 4 mL bottle            NDC 0065-1750-07</paragraph>
                  <paragraph>3 mL in 4 mL bottle               NDC 0065-1750-14</paragraph>
                  <paragraph>
                     <content styleCode="bold">Storage:</content> Store at 2°C-25°C (36°F-77°F).</paragraph>
                  <paragraph>Protect from light.</paragraph>
               </text>
               <effectiveTime value="20190131"/>
            </section>
         </component>
         <component>
            <section>
               <id root="ac79823e-88d9-404e-a909-5da595e8f342"/>
               <code codeSystem="2.16.840.1.113883.6.1" code="34076-0" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Slow or Delayed Healing</content>
                  </paragraph>
                  <paragraph>Inform the patient of the possibility that slow or delayed healing may occur while using NSAIDs <content styleCode="italics">[see Warnings and Precaution (5.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Avoiding Contamination of the Product</content>
                  </paragraph>
                  <paragraph>Instruct the patient to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular infections. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.</paragraph>
                  <paragraph>Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Contact Lens Wear</content>
                  </paragraph>
                  <paragraph>ILEVRO<sup>*</sup> 0.3% should not be administered while wearing contact lens <content styleCode="italics">[see Warnings and Precautions (5.4)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Intercurrent Ocular Conditions</content>
                  </paragraph>
                  <paragraph>Advise the patient that if they develop an intercurrent ocular condition (e.g., trauma, or infection) or have ocular surgery, they should immediately seek their physician’s advice concerning the continued use of the multi-dose container <content styleCode="italics">[see Warnings and Precaution (5.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Concomitant Topical Ocular Therapy</content>
                  </paragraph>
                  <paragraph>If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart <content styleCode="italics">[see Dosage and Administration (2.2)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Shake Well Before Use</content>
                  </paragraph>
                  <paragraph>Patients should be instructed to shake well before each use <content styleCode="italics">[see Dosage and Administration (2.1)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="bold">ALCON<sup>®</sup>
                     </content>
                     <br/>a Novartis Company
						</paragraph>
                  <paragraph>Distributed by:<br/>Alcon Laboratories, Inc.<br/>Fort Worth, Texas 76134 USA</paragraph>
                  <paragraph>©2014, 2019 Novartis</paragraph>
                  <paragraph>*a trademark of Novartis</paragraph>
                  <paragraph>T2019-21</paragraph>
               </text>
               <effectiveTime value="20190131"/>
            </section>
         </component>
         <component>
            <section ID="ID_fa816387-61b4-d0d6-fc2d-3571b4684189">
               <id root="96f19314-4202-45c0-8c6d-526c54823e28"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC</content> 0065-1750-07             <content styleCode="bold">STERILE<br/>
                     </content>
                     <br/>
                     <content styleCode="bold">ILEVRO<sub>™</sub>
                        <br/>(nepafenac ophthalmic<br/>suspension) 0.3%<br/>
                     </content>
                     <br/>1.7 mL<br/>
                     <content styleCode="bold">Alcon<sup>®</sup>
                     </content>
                  </paragraph>
                  <renderMultiMedia referencedObject="MM36793"/>
               </text>
               <effectiveTime value="20181213"/>
            </section>
         </component>
      </structuredBody>
   </component>
</document>